Arturo Molina MD - 15 Nov 2023 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role: Chief Medical Officer
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Issuer symbol: PTGX
Transactions as of: 15 Nov 2023
Net transactions value: -$30,012
Form type: 4
Filing time: 04 Jan 2024, 20:09:17 UTC
Previous filing: 18 Jan 2023
Next filing: 18 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTGX	Common Stock	Sale	$30,012	-1,848	-7.6%	$16.24	22,527	15 Nov 2023	Direct	F1
transaction	PTGX	Common Stock	Award	$0	+26,250	+117%	$0.000000	48,777	02 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTGX	Stock Option (right to buy)	Award	$0	+97,500		$0.000000	97,500	02 Jan 2024	Common Stock	97,500	$23.42	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.
F2	Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F3	The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.